- Open Access
- Open Peer Review
Evaluating the feasibility of a pharmacist-guided patient-driven intervention to improve blood pressure control in patients with CKD
© The Author(s). 2019
- Received: 24 October 2018
- Accepted: 31 January 2019
- Published: 12 February 2019
Self-titration of blood pressure (BP) medications and lifestyle modifications are effective and safe strategies to lower BP. We assessed the feasibility of implementing a pharmacist-guided, patient-driven self-titration protocol and standardized dietary counseling to improve BP in the chronic kidney disease (CKD) clinic.
Adult patients seen in the CKD clinic were identified via registry screening. Inclusion criteria were as follows: a diagnosis of hypertension, average of the last 3 office BP > 150/90 mmHg, and prescribed 3 or fewer BP medications. Patients with severe hypertension were excluded. BP goals were established and patients were referred to the clinical pharmacist who provided them a BP cuff, a BP medication titration plan (based on home BP monitoring), and dietary education. The following outcomes were evaluated: appeal of the program to patients identified by the registry, patient adherence to the protocol and 6-month office BP, and provider attitudes and acceptance of the protocol.
Seventeen patients enrolled in the pilot, the majority recruited via clinic schedule screening. Eleven of the 17 patients completed a 6-month office follow-up visit. Three of the 11 patients met their pre-specified office BP goal. There was, however, significant improvement in 6-month office systolic and diastolic BP. Twelve of 17 patients were adherent to entering home BP in EMR. Provider satisfaction with the protocol was high.
Our preliminary data suggest that patient-driven self-titration of BP medications is feasible and well received by providers. Future studies are needed to validate these findings and to evaluate the safety and efficacy of this approach.
- Blood pressure
- Implementation science
Hypertension is one of the most important risk factors for renal and cardiovascular morbidity and mortality . Despite advances in therapy strategies and attention placed on target blood pressure (BP) goals, only about two thirds of treated patients reach their pre-specified BP goal . New trials demonstrate the benefits of stricter BP control, and the most recent guidelines (released by the American Heart Association) reflect the overwhelming benefit of tighter BP control demonstrated in these trials [3, 4]. As goal blood pressures are lowered, it will be harder for patients to attain the target BP .
The population cared for in the chronic kidney disease (CKD) clinic presents a special challenge in terms of hypertension management. First, patients CKD often have hypertension secondary to their underlying kidney disease and are more likely to be resistant to first-line therapy than individuals without CKD . Second, patients with CKD are known to be at elevated cardiovascular risk compared to the general population, making BP control all the more important for this group of patients and BP goals more stringent, particularly in those with glomerular disease [6, 7].
In most practices, licensed providers perform the bulk of hypertension management. This is despite evidence of the effectiveness of patient-dependent self-monitoring and titration protocols [8–12]. Such approaches engage patients in their care and eliminate the lag time inherent in waiting for the next appointment to intensify therapy in response to uncontrolled BP [8, 9]. Taking this a step further, self-management of hypertension consisting of self-monitoring of home BP and the implementation of a simple pre-determined titration plan by the patient has been shown to be more effective at lowering systolic BP than the usual care [11, 12]. Additionally, well-conducted studies have demonstrated the importance of dietary approaches to augment BP control [13, 14]. While the Dietary Approach to Systolic Hypertension (DASH) diet has become popular in niche groups for dieters, published data in the last decade indicate low rates of lifestyle modification counseling by providers for patients with hypertension worldwide, being less than 50% in the majority of reports [15–19].
The results of clinical trials have found limited implementation into clinical practice, and it remains unclear whether such interventions are feasible in clinical practice. Furthermore, the recent governmental push to increase use of electronic medical record (EMR) systems which have the capabilities to pool data and create specific population registries present an opportunity to modify the health of a patient population at large and to evaluate whether identifying patients via EMR screening is feasible and/or effective. The overall objective of this pilot project was to evaluate the feasibility of implementing an interdisciplinary approach for the management of BP in a CKD clinic. Specifically, we evaluated the feasibility of implementing a pharmacist-guided patient-driven approach for self-monitoring and self-titration of BP medications and the integration of dietary counseling as a routine component of BP management in a CKD clinic.
Subjects and setting
The pilot took place in the CKD clinic, a subspecialty multidisciplinary clinic of 25 providers including physicians and advanced practice providers, at the University of Colorado Anschutz Medical Center. The proposal was funded by a Clinical Effectiveness and Patient Safety Small grants program, an institutional grant awarded after a peer review process. An application was submitted for approval of the project to the Institutional Review Board. Considering the nature of the intervention and the setting, this was approved to proceed as a quality improvement initiative. Since this was approved as a quality improvement initiative, informed consent was not required or obtained.
The CKD clinic at UCH is staffed by a clinical renal nurse, a dietician, and a clinical pharmacist. In 2015, 718 patients were identified as hypertensive in the CKD clinic. Of these, the most recent blood pressure was < 140/90 mmHg in only 423 (59%). This cutoff was chosen based on the JNC 8 guidelines, which were the most recent guidelines for goal BP at the time of the protocol design . The CKD clinic BP management follows a traditional approach, medication adjustments are made by the provider during the clinic visit, and future titrations hinge on future face-to-face follow-up visits with the provider. The CKD clinic utilizes Epic EMR, and the patients are offered access to the patient portal (My Health Connection, EPIC propriety).
Adult patients seen in the CKD clinic between August 1, 2015, and August 1, 2016, were eligible to participate if they had a diagnosis of hypertension and an average of the last 3 office BP readings > 150/90 mmHg. Additionally, the inclusion criteria required the following: potential participants were receiving three or fewer BP medications (in order to allow for up-titrations) and the participants were willing to participate. Exclusion criteria included the following: BP > 200/100 mmHg, life-limiting illness, or dementia.
Our protocol was adapted based on studies by McManus et al. that showed patient self-titration of BP medications was effective and safe in patients with high BP including those with high-risk conditions such as underlying cardiovascular disease or CKD [11, 12]. Initially, patients were identified for participation by screening EPIC CKD or HTN registry reports in HealthyPlanet. The following criteria were applied in the search: (1) patients seen between 8/5/15 and 8/5/16 in the department “AMC KID HTN”, (2) patient status not equal to deceased, (3) age 18–85 years, and (4) last DBP ≥ 90 mmHg and last SBP 150–199 mmHg. When patients were contacted, their interest in participation and ability to interact with the patient portal My Health Connection was assessed. The primary renal provider (physician or advanced practice provider) was alerted of participation and cosigned the order to initiate the patient’s first visit with the clinical pharmacist.
Patients who agreed to participate were scheduled for a 60-min visit with the clinical pharmacist with the following objectives: devise an individualized titration plan, educate the patient on correct BP measurement technique and how to record readings in My Health Connection, and provide an introduction to DASH diet. Additionally, all patients with estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 were offered a referral to the registered dietician within the CKD clinic. Patients were provided their own automated BP cuffs. We used the A&D Medical model # UA-611 BP monitor (https://medical.andonline.com/product/blood-pressure-monitor/ua-611).
The clinical pharmacist utilized the Collaborative Drug Therapy Management protocol  to develop and implement an individualized therapeutic plan for each patient. They developed an algorithm for each patient aimed to maximize the dosage of each medication in a stepwise fashion and then to add an additional agent in a rational order to exhaust first-line therapy prior to advancing to second- and third-line agents. Patients were assigned a home BP goal, which was based on personal risk factors and best evidence available [4, 22, 23]. Patients were instructed to measure their BP a minimum of 6 times per week  and record it into My Health Connection, which was accessible to both the patient and the clinical pharmacist. A medication titration was triggered if greater than 30% of measurements were above goal in a 2-week interval . We anticipated home BP should be 5 mmHg lower than office BP. Hence, if goal office BP is < 140/90 mmHg, then medication adjustments would be prompted by 3 out of 10 home BP readings > 135/85 mmHg . Patients would communicate with the pharmacist via EMR when a titration had been made and the pharmacist would update the medication list and order the appropriate follow-up labs if needed. When patients were unable to communicate via EMR, they would communicate with the clinic nursing staff via telephone or email and the clinic nurse would enter a note in EMR to notify the pharmacist.
The dietary information given to patients was scripted. If a patient’s eGFR was greater than 60 ml/min/1.73m2, the information was based on DASH principles. As DASH places a high emphasis on high potassium foods, patients with eGFR < 60 ml/min/1.73m2 were offered a visit with a dietitian and provided information on low sodium strategies without the emphasis on high potassium.
Outcomes and measures
The following outcomes were evaluated: appeal of the program to patients identified by the HealthyPlanet registry, patient adherence to the protocol, and provider attitudes and acceptance. We intended to evaluate the appeal of the program to patients as proportion of patients (identified by the registry) who agreed to participate. Patient adherence was evaluated as the number of participants that entered their home BP readings by My Health Connection and number of participants that presented for the 6-month follow-up visit. In addition, we evaluated the number of BP entries per patient. Office BP was evaluated at baseline and at the 6-month office visit. CKD provider appeal was evaluated as the number and % of providers who accepted the pended order for referral to the clinical pharmacist. Additionally, CKD provider attitudes toward this approach were assessed utilizing a 17-item survey both before the project started and after 9 months of project run time. The surveys were anonymous and conducted using the Survey Monkey platform as this allowed the team to create an online survey with basic computer skills without additional cost . Secondary outcomes included number of medication titrations or initiations performed. Additionally, we evaluated the following secondary exploratory outcomes: office BP at 6 months, BP change from baseline, and the number (%) of patients who achieved pre-specified BP goals.
The following process matrices were evaluated: the % of participants seen by the clinical pharmacist and given a detailed titration plan, the % of participants given dietary education or offered a formal dietary consult, and the % of participants provided with a BP cuff and given instructions to manually enter readings into the interactive function of the EMR.
Patient safety monitoring
Patients were contacted 3 months into participation and asked about the occurrence of any adverse events that could be associated with their antihypertensive therapy. This phone call was conducted by the renal nurse and documented in EMR and sent to the clinical pharmacist. Additionally, after 6 months of participation, a follow-up clinical visit was scheduled with the clinical pharmacist to assess progress.
For descriptive statistics, mean ± SD are provided for continuous variables (e.g., BP) and proportion for categorical variables. The following variables were evaluated: proportion of patients achieving BP goal, proportion of patients who agreed to participate, number of participants that entered their home BP readings by My Health Connection at the designated intervals, and number of participants that presented for the 6-month follow-up visit. In addition, the number and percentage of providers who accepted the pended order for referral to the clinical pharmacist was assessed. The paired t test was used in pre-post comparison of BP, and the McNemar exact test was performed as appropriate in comparison of dichotomized variables with pre-post BP measures, without pre-specified statistical power because of the pilot and exploratory nature of the study. Additionally, we utilized non-parametric testing (Spearman’s rank) to explore the potential correlation between the number of BP entries in EMR and the change in office BP at the 6-month follow-up visit. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
Appeal of the program to patients identified by registry screening
Baseline characteristics for all participants
Age, mean years (SD)
Female sex, n (%)
Black race, n (%)
Systolic blood pressure, mean mmHg (SD)
Diastolic blood pressure, mean mmHg (SD)
Diabetic, n (%)
eGFR, mean ml/min/1.73 m2 (SD)
eGFR < 60 ml/min/1.73 m2, n (%)
Number of antihypertensive agents (mean)
Antihypertensive class, n (%)
Calcium channel blocker
Patient adherence and office BP at 6 months
Patient study data
Study ID #
Change in SBP*
Change in DBP*
Provider attitudes and acceptance of the protocol
The pharmacy service supports clinical decision-making for management of BP medications
Pharmacist-guided patient-driven up-titration of BP medications improves physician and provider satisfaction
Lifestyle and dietary modifications are an integral part of BP management and should be applied routinely in clinical practice
All of the enrolled patients (100%) were given a detailed titration plan. All of the enrolled patients (100%) were given dietary education, and 100% were offered referral for formal dietary consult. Similarly, 100% of patients were provided with a BP cuff and given instructions to manually enter readings into the interactive function of the EMR. An issue we encountered initially was patients’ inability/lack of experience with using the EMR patient portal My Health Connection, despite providing the instructions. We subsequently planned on the clinical pharmacist educating patients on entering their BP in EMR. However, this was not possible as some patients did not have access to their EMR patient portal function. We subsequently provided a letter of instructions to the patients regarding the importance of establishing an access account for the portal prior to visit with the clinical pharmacist. Once that was implemented, we noted a significant improvement in adherence as reported above.
One patient had symptomatic hypotension subsequent to the prescribed medication up-titration plan. This patient communicated with the CKD clinic nursing staff, and their medications were withheld leading to resolution of symptoms without further intervention. The clinic nursing staff entered a note in epic and notified the clinical pharmacist per the protocol. We observed no other adverse events.
We have demonstrated, for the first time, that pharmacist-guided patient-driven titration of BP medications is feasible and well-received by providers in a subspecialty clinic at a major academic medical center. Importantly, our data suggest that such a program improves BP control. While a small proportion of patients met their pre-specified office BP goal at the 6-month visit, a much greater proportion of patients demonstrated improvement in their BP readings. One lesson from recent studies is that the general improvement in BP offers significant benefits even when patients do not achieve their pre-specified goal . As such, our findings, while preliminary, provide a potentially novel approach that could have a significant impact on the management of high BP in clinical practice.
Our protocol was adapted based on studies by McManus et al. that showed patient self-titration of BP medications was effective and safe in patients with high BP including those with high-risk conditions such as our patient population [11, 12]. However, no studies to date have evaluated the feasibility of implementing this approach in a clinical practice setting. In addition, in the studies by McManus et al., the physician outlined the BP medication plan for the patients, whereas in our pilot, we utilized the clinical pharmacist. We elected this approach based on data that pharmacist/physician co-management of blood pressure is associated with improved BP lowering [27, 28]. As such, although our protocol was adapted based on previous studies, it is novel in and of itself due to the utilization of a broader group of interdisciplinary team members including the provider, the clinical pharmacists, the clinic dietician, and the patient.
Our protocol was not designed to measure adherence with dietary counseling or with medications. As such, one might argue that the improved BP readings in our patients represent improved adherence with either or both. However, all but one patient experienced intensification of their medication regimen per their titration plan. Though speculative, our approach likely led to BP control more rapidly than the traditional practice of titrating BP medications in clinic during face-to-face visits. Evaluating the time needed to achieving BP target was beyond the scope of this pilot. However, based on our findings, we believe that future studies designed to evaluate the effectiveness of this approach should evaluate this outcome.
Implementing our pilot as a quality improvement project allowed us to adapt our approach to better understand what would be feasible in our clinical setting. For example, our initial plans to utilize search functionality of pre-existing CKD and hypertension registries to identify potential patients did not yield as many participants as we had intended. There were several reasons for this. First, the initial screening process identified multiple patients who did not have a designated Renal Provider in our practice (a provider signature was required on the protocol order). This was despite the discrete search criteria including our clinical area. Second, it was not always readily apparent from the documentation in the patient’s medical record whether patients met enrollment criteria based on BP, and a considerable number of patients reviewed did not meet the inclusion criteria due to having either above cutoff or below cutoff BP. Third, many patients were on > 3 medications, and considering the nature of high BP in patients with CKD and the complexity of the medical regimen in this group of patients, future work should evaluate this approach in patients on more than 3 medications as well. Fourth, “cold-calling” patients identified via registry searches yielded low enrollment, possibly because some patients perceived they were being recruited to participate in a research study as opposed to utilizing a different approach for their everyday care. Patient recruitment improved with a clinic schedule-based approach that incorporated our nursing staff in a proactive screening process. This is an important finding that should be considered in future study design.
Another barrier that we encountered that limited implementation of the original plan was patients’ inability/lack of experience using the EMR patient portal as a tool to track their progress. We subsequently provided a letter of instructions to the patients regarding the importance of establishing an access account prior to the visit with the clinical pharmacist and the clinical pharmacist educated the patient the use of the interactive EMR function. This led to substantial improvement in adherence. Our findings here signal the importance of identifying other approaches for patient interface with EMR in the future. For example, the authors are aware of BP cuffs which automatically transmit data to the EMR; however, the cost was prohibitive for this pilot proposal. We ultimately achieved a high rate of adherence with self-entry of BP readings into the EMR which we believe was due to the high level of motivation by the participating patients and the dedication of our team in overcoming this barrier. In fact the high level of patient motivation may represent selection bias in the interpretation of our data. It should also be noted that self-management strategies are not ideal for every patient. Successful implementation of such strategies requires a motivated patient with some degree of health literacy. Future studies should focus on patient factors that may influence the feasibility and sustainability of such an approach. Alternatively, a more proactive approach by the clinical pharmacist may be necessary such as routine follow-up calls to evaluate BP response and adherence with the medication titration plan .
In addition to a motivated patient, providers must be willing to rely on the patient to assume a greater degree of autonomy with regard to medication management and on the clinical pharmacist for the monitoring of labs such as creatinine and potassium. Despite the high provider satisfaction rates with the protocol in our setting, we recognize this may not be generalizable. Some patients require the face-to-face attention gained in the traditional approach for the management of hypertension. Additionally, it is conceivable that such an approach for the management of high BP in patients with CKD may result in fewer provider visits. Due to the pilot nature of the project and the limited follow-up time, we were unable to evaluate clinic attendance times and how this may further influence the clinical practice. Further work is needed to better understand the clinical settings in which such an approach can be implemented. It is important to exercise caution in the interpretation of the exploratory efficacy outcomes reported here given the nature of the study design (to evaluate the feasibility of the intervention), the small sample size, and the paucity of data.
Our findings demonstrate that implementation of a pharmacist-guided self-titration program is feasible and can lead to improved BP control in select patients. In our study, registry screening was not an effective tool for identifying patients with uncontrolled hypertension who might benefit from the developed intervention. We believe that our findings are important to inform future studies on the topic. Further work is needed to validate our preliminary data and to evaluate the safety and the efficacy of pharmacist-guided patient-driven self-titration on BP control in clinical practice.
We would like to thank Dr. Lisa Schilling and Dr. Michael Ho for their input in the original project’s design.
The project was funded by a Clinical Effectiveness and Patient Safety Small grants program. This is an institutional grant offered by the University of Colorado Anschutz Medical Center that awards grants for Quality Improvement Initiatives after a peer review process. This study analysis was supported in part by The University of Iowa Clinical and Translational Science Award granted with funds from the NIH (UL1TR002537). Additionally, Dr. Hopley, was funded by training grant T32 DK007135.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
CH was responsible for the goal blood pressure definition, provider survey, data analysis, and manuscript writing. EA was responsible for the regulatory issues, projects design and implementation, patient recruitment and registry reports, data collection, and manuscript edits. PK was responsible for the project design and implementation, pharmacist visits, and manuscript edits. MJ was responsible for the project design and implementation, patient safety monitoring, and data collection. AG was responsible for the dietary counseling, materials design, and manuscript edits. PTE was responsible for the data analysis. ZY was responsible for the project design, statistical analysis plan, and manuscript edits. SJB was responsible for the project design, data analysis and interpretation, and manuscript edits. CL was responsible for the project design, data analysis and interpretation, and manuscript edits. KK was responsible for the data interpretation and critical manuscript edits. BD was responsible for the data interpretation and critical manuscript edits. DJ was responsible for the project conception, project design and implementation, data analysis and interpretation, and final manuscript draft. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The project was submitted for approval to the Colorado Institutional Review Board (COMIRB) with a declaration of the intent to publish. COMIRB viewed the pilot as a quality improvement initiative, and the review was waived. As such, informed consent was not required or obtained.
Consent for publication
Not applicable as the manuscript does not contain any individual data.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.View ArticleGoogle Scholar
- Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311(14):1424–9.View ArticleGoogle Scholar
- Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.View ArticleGoogle Scholar
- Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.View ArticleGoogle Scholar
- Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386(10003):1588–98.View ArticleGoogle Scholar
- Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant. 2008;23(12):3851–8.View ArticleGoogle Scholar
- Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157(13):1413–8.View ArticleGoogle Scholar
- Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens (Greenwich, Conn). 2006;8(3):174–80.View ArticleGoogle Scholar
- Bray EP, Holder R, Mant J, McManus RJ. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med. 2010;42(5):371–86.View ArticleGoogle Scholar
- Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310(1):46–56.View ArticleGoogle Scholar
- McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376(9736):163–72.View ArticleGoogle Scholar
- McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312(8):799–808.View ArticleGoogle Scholar
- Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170(2):126–35.View ArticleGoogle Scholar
- Blumenthal JA, Babyak MA, Sherwood A, Craighead L, Lin PH, Johnson J, et al. Effects of the dietary approaches to stop hypertension diet alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids. Hypertension. 2010;55(5):1199–205.View ArticleGoogle Scholar
- Ardery G, Carter BL, Milchak JL, Bergus GR, Dawson JD, James PA, et al. Explicit and implicit evaluation of physician adherence to hypertension guidelines. J Clin Hypertens. 2007;9(2):113–9.View ArticleGoogle Scholar
- Bell RA, Kravitz RL. Physician counseling for hypertension: what do doctors really do? Patient Educ Couns. 2008;72(1):115–21.View ArticleGoogle Scholar
- Booth AO, Nowson CA. Patient recall of receiving lifestyle advice for overweight and hypertension from their General Practitioner. BMC Fam Pract. 2010;11:8.View ArticleGoogle Scholar
- Mellen PB, Palla SL, Goff DC Jr, Bonds DE. Prevalence of nutrition and exercise counseling for patients with hypertension. United States, 1999 to 2000. J Gen Intern Med. 2004;19(9):917–24.View ArticleGoogle Scholar
- Johnson HM, Olson AG, LaMantia JN, Kind AJ, Pandhi N, Mendonca EA, et al. Documented lifestyle education among young adults with incident hypertension. J Gen Intern Med. 2015;30(5):556–64.View ArticleGoogle Scholar
- James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.View ArticleGoogle Scholar
- American College of Clinical P, McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, et al. Collaborative drug therapy management and comprehensive medication management-2015. Pharmacotherapy. 2015;35(4):e39–50.View ArticleGoogle Scholar
- Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.View ArticleGoogle Scholar
- Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.View ArticleGoogle Scholar
- Sharman JE, Blizzard L, Kosmala W, Nelson MR. Pragmatic method using blood pressure diaries to assess blood pressure control. Ann Fam Med. 2016;14(1):63–9.View ArticleGoogle Scholar
- Pickering TG, White WB, American Society of Hypertension Writing G. ASH position paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Clin Hypertens. 2008;10(11):850–5.View ArticleGoogle Scholar
- Van Hout MC, Crowley D, McBride A, Delargy I. Piloting online self-audit of methadone treatment in Irish general practice: results, reflections and educational outcomes. BMC Med Educ. 2018;18(1):153.View ArticleGoogle Scholar
- Weber CA, Ernst ME, Sezate GS, Zheng S, Carter BL. Pharmacist-physician comanagement of hypertension and reduction in 24-hour ambulatory blood pressures. Arch Intern Med. 2010;170(18):1634–9.View ArticleGoogle Scholar
- Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens. 2008;10(4):260–71.View ArticleGoogle Scholar
- Kennelty KA, Polgreen LA, Carter BL. Team-based care with pharmacists to improve blood pressure: a review of recent literature. Curr Hypertens Rep. 2018;20(1):1.View ArticleGoogle Scholar